Chemical Properties:
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Brexpiprazole Intermediates Brexpiprazole CAS 913611-97-9 7-Hydroxyquinolinone CAS 70500-72-0 4-Bromobenzo[b]thiophene CAS 5118-13-8 1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8 4-Chlorobenzo[b]thiophene CAS 66490-33-3| Item | Specifications |
| Appearance | Colorless Liquid |
| Purity / Analysis Method | >98.0% (GC) |
| Total Impurities | <2.00% |
| Infrared Spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Brexpiprazole (CAS: 913611-97-9) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 4-Chlorobenzo[b]thiophene |
| Synonyms | 4-Chloro-Benzo[b]thiophene; 4-Chloro-1-Benzothiophene; 4-Chlorobenzothiophene |
| CAS Number | 66490-33-3 |
| CAT Number | RF-PI1983 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C8H5ClS |
| Molecular Weight | 168.64 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
4-Chlorobenzo[b]thiophene (CAS: 66490-33-3) is an Intermediate of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is a novel antipsychotic drug which serves as a serotonin ® dopamine activity modulator and has demonstrated efficacy as an adjunctive treatment in patients with major depressive disorder (MDD). The drug exhibits a unique pharmacological profile, acting as a partial agonist of serotonin 5-HT1A and dopamine D2 receptors and as a full antagonist of 5-HT2A and noradrenaline α1B/2C receptors, with similar subnanomolar binding affinity. The drug, which was developed by Otsuka and Lundbeck, was approved in 2015 by the FDA for the treatment of schizophrenia and as an adjunctive treatment for depression. Brexpiprazole is widely considered to be a successor to Otsuka’s antipsychotic drug aripiprazole (trade name Abilify) whose patent expired in August 2014.
